Journals / Çocuk Acil ve Yoğun Bakım Dergisi / 2015 / Cilt: 2 - Sayı: 1

A Life Threatening Arrhythmia Case Caused by Use of Milrinone

Milrinon Kullanımına Bağlı Gelişen ve Yaşamı Tehdit Eden Aritmi Olgusu

Pages
31–34
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: We thought t to present the case due to the contribution it might bring to the intensive care practice by keeping in mind life threatening arrhythmias related to milrinone CAYD 2015;2(1):31-34.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Background: Milrinone is a phosphodiesterase III inhibitor which is used very often in pediatric cases post-cardiac operation and in intensive care unit for hemodynamic support.
📊
Key Findings & Data:However it is known that Milrinone has side eects such as headache, angina, hypotension, anaphylaxis, hypokalemia, deterioration of liver functions, thrombocytopenia, as well as supraventricular tachycardia, ventricular tachycardia, torsade de pointes, atrial brillation and sometimes ventricular brillation.
💡
Conclusion & Impact:Conclusion: We thought t to present the case due to the contribution it might bring to the intensive care practice by keeping in mind life threatening arrhythmias related to milrinone CAYD 2015;2(1):31-34.
🔬Design:Research Article
📍Scope:2015 Verileri
⚙️Variables:Domain Parameters

Abstract

Background: Milrinone is a phosphodiesterase III inhibitor which is used very often in pediatric cases post-cardiac operation and in intensive care unit for hemodynamic support. However it is known that Milrinone has side eects such as headache, angina, hypotension, anaphylaxis, hypokalemia, deterioration of liver functions, thrombocytopenia, as well as supraventricular tachycardia, ventricular tachycardia, torsade de pointes, atrial brillation and sometimes ventricular brillation. Case report: In our case, where a one year old patient was interned into intensive care for cardiomyopathy and heart failure, who was given Milrinone infusion for hemodynamic support, after which he developed ventricular brillation; We think that life threatening ventricular brillation is related to milrinone due to the fact that after ending milrinone infusion the arrhythmia didn't repeated. Conclusion: We thought t to present the case due to the contribution it might bring to the intensive care practice by keeping in mind life threatening arrhythmias related to milrinone CAYD 2015;2(1):31-34.

Özet

Giriş: Milrinon postop kardiyak olgularda ve yoğun bakım ünitelerinde hemodinamik destek için sıklıkla kullanılan birfosfodiesteraz III inhibütörüdür. Milrinonun bilinen baş ağrısı, angina, hipotansiyon, anafilaksi, hipokalemi, karaciğerfonksiyon bozukluğu, trombositopeni gibi yan etkilerinin yanı sıra, supraventriküler taşikardi, ventriküler taşikardi, torsade depointes, atrial fibrilasyon ve bazen ventriküler fibrilasyon gibi yan etkileri de olabilmektedir.Olgu: Bir yaşında hasta kardiyomiyopati ve kalp yetmezliği nedeniyle yoğun bakım ünitesine yatırıldı, hemodinamikdestek için milrinon infüzyonu verildi. Ardından hastada ventriküler fibrilasyon gelişti, milrinon infüzyonununkesilmesinin ardından aritminin tekrarlamaması üzerine milrinona bağlı hayatı tehdit eden bir ventriküler fibrilasyonolduğunu düşündük.Sonuç: Bu olguyu sunmamızdaki amacımız, yoğun bakım ünitelerinde hayatı tehdit eden aritmilerin milrinona bağlıolarak ta gelişebileceğini akılda tutmamız açısından önemli olabileceğini vurgulamaktır CAYD 2015;2(1):31-34.

🔖

Cite This Article

HOROZ, Ö. Ö., YILDIZDAŞ, R. D., PETMEZCİ, E., SARI, M. Y., GÜLLÜ, U. U. (2015). A Life Threatening Arrhythmia Case Caused by Use of Milrinone. Çocuk Acil ve Yoğun Bakım Dergisi, Cilt: 2 - Sayı: 1, 31–34. https://ajindex.com/articles/203500

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (7)

  1. Ramamoorthy C, Anderson GD, Williams GD et al. Pharmacokinetics and Side Effects of Milrinone in Infants and Children After Open Heart Surgery. Anesth Analg. 1998; 86:283-9.
  2. Lindsay CA, Barton P, Lawless S et al. Pharmacokinetics and Pharmacodynamics of Milrinone Lactate in Pediatric Patients With Septic Shock. J Pediatr. 1998; 132:329-34.
  3. Gregory A. Fleming, Katherine T. Murray, Chang Yu, John G. Byrne, James P. Greelish et al. Milrinone use is associ- ated with postoperative atrial fibrillation after cardiac sur- gery. Circulation. 2008; 118:1619-1625.
  4. Andrew H. Smith, Jill Owen, Kristie Y. Borgman, Frank A. Fish, Prince J. Kannankeril. Relation of Milrinone After Surgery for Congenital Heart Disease to Significant Postoperative Tachyarrhythmias. The American Journal of Cardiology. 2011; 108: 1620-1624.
  5. Majure DT, Greco T, Greco M, Ponschab M, Biondi-Zoccai G et al. Meta-analysis of Randomized Trials of Effect of Milrinone on Mortality in Cardiac Surgery: An Update. Cardiothorac Vasc Anesth. 2013; 27:220-9.
  6. Lechner E, Hofer A, Leitner-Peneder G. Levosimendan ver- sus milrinone in neonates and infants after corrective open-heart surgery: A pilot study. Pediatr Crit Care Med. 2012; 13:542-548.
  7. Hoffman TM, Wernovsky G, Atz AM. Efficacy and safety of milrinone in preventing low cardiac output syndrome in infants and children after corrective surgery for congeni- tal heart disease. Circulation. 2003; 107:996-1002.